Navigating Insulin-Based Therapy for Type 2 Diabetes

T2DM and CV Risk Program Image
Apply new studies on NPH, regular insulin, switching, and other approaches to avoid hypoglycemia, control hyperglycemia, and reduce CV risk with this module.
Veronica K. Piziak, MD, PhD, FACP
Program Director
Released: January 11, 2019 Expiration: No longer available for credit

Related Content

Short commentary from Dr. Martin Abrahamson on using SGLT2 inhibitors for cardiovascular and renal disease with type 2 diabetes, from CCO

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: November 10, 2020 Expired: November 9, 2021

CME commentary: GLP-1 receptor agonists and weight reduction in diabetes. Evidence for exenatide, dulaglutide, liraglutide, semaglutide in T2D and obesity.

Robert S. Zimmerman, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: October 26, 2020 Expired: October 25, 2021

Expert recommendations from Clinical Care Options on using oral semaglutide to treat type 2 diabetes

Richard E. Pratley, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: October 22, 2020 Expired: October 21, 2021

Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes

Martin J. Abrahamson, MD, FACP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 1, 2020 Expired: August 31, 2021
Provided by Southern Medical Association
Southern Medical Association logo

Southern Medical Association, CME Division
3500 Blue Lake Drive, Suite 360
Birmingham, AL 35243
Tel: 800.423.4992, ext. 620
Email:  Education@sma.org
Website: http://sma.org

Supported by an educational grant from
Lilly USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue